Market capitalization | $5.65m |
Enterprise Value | $-2.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.29 |
P/B ratio (TTM) P/B ratio | 0.75 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.53m |
Free Cash Flow (TTM) Free Cash Flow | $-8.02m |
Cash position | $8.02m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a Hoth Therapeutics, Inc. forecast:
2 Analysts have issued a Hoth Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -7.53 -7.53 |
32%
32%
|
EBIT (Operating Income) EBIT | -7.53 -7.53 |
32%
32%
|
Net Profit | -7.51 -7.51 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
Head office | United States |
CEO | Robbie Knie |
Employees | 6 |
Founded | 2017 |
Website | www.hoththerapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.